Improving Genome editing for Therapeutic Purposes: A conversation with John Finn, Chief Scientific Officer at Tome Biosciences

Tome Biosciences is revolutionizing genome editing with its programmable genomic integration technology, offering a precise and efficient approach to developing genomic medicines.

Tome Biosciences is pioneering the use of programmable genomic integration (PGI) to develop a new class of genomic medicines. In this interview, John Finn, Chief Scientific Officer at Tome, discusses the potential of PGI, its advantages over other genome editing approaches, and its impact on the future of genomic medicine discovery.


PGI enables the insertion of any size DNA into a specific location in the genome. Unlike other integration systems, PGI is fully programmable, allowing for precise targeting of DNA insertion. Tome’s technology, based on Cas9 and integrases, writes a landing site at a specific location and integrates a large DNA template at that site. This approach offers high efficiency and specificity, crucial for therapeutic applications.



PGI offers several advantages over other technologies, such as CRISPR. It uses nickases, reducing the risk of off-target mutations. Additionally, PGI does not generate double-strand breaks (DSBs), minimizing the risk of translocations. Tome’s technology has shown high efficiency in integrating large DNA sequences, making it suitable for complex cell therapies.


Tome plans to continue advancing its PGI technologies and presenting its work at scientific conferences in 2024. The company is focused on preclinical testing of its integrative gene therapy and cell therapy platforms. Additionally, Tome is exploring novel delivery methods and constantly enhancing its PGI technologies.


In the next three to five years, Finn predicts a rise in approved CRISPR-based medicines, leading to increased interest in gene editing. He foresees the use of gene editing in pediatric applications to potentially cure children before they become sick. There will also be a shift towards editing common diseases affecting a larger population.

Tome Biosciences’ innovative approach to genome editing holds great promise for advancing genomic medicine and addressing critical medical needs.